Asian Journal of Research in Social Sciences and Humanities
ISSN: 2249-7315 Vol. 11, Issue 11, November 2021 SJIF 2021 = 8.037
A peer reviewed journal

AN OVERVIEW ON DIAGNOSIS AND PREVENTION OF ISCHAEMIC STROKE

Mahendra Singh*

*Assistant Professor
Department of Agricultural Sciences,
Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India
Email id: bhahuni.singh65@gmail.com
DOI: 10.5958/2249-7315.2021.00210.0

ABSTRACT

Acute ischemic stroke is a significant public health concern that will become more important to neurologists in the future. Timely reperfusion therapy remains the cornerstone of successful stroke management. This necessitates public and first responder identification of symptoms early on, triage to a suitable stroke center, and rapid evaluation and investigation by the attending stroke team. In properly chosen patients, intravenous thrombolysis and/or endovascular thrombectomy are used to accomplish recanalisation and reperfusion of the ischemic penumbra. All patients should be admitted to an acute stroke unit for careful monitoring to avoid subsequent problems and early neurological impairment. Patients may begin appropriate secondary preventive therapy as soon as the mechanism of stroke is identified. Future goals include making endovascular thrombectomy more accessible, extending treatment windows with improved imaging, and finding neuroprotective medicines to avoid subsequent neuronal injury.

KEYWORDS: *Diagnosis, Ischamic Stroke, Management, MRI, Prevention.*

INTRODUCTION

In the United Kingdom, stroke is the fourth greatest cause of mortality and the main cause of adult neurological impairment. The accompanying socioeconomic impact is enormous; the total cost of a stroke is projected to be £25.6 billion per year, including long-term healthcare, rehabilitation, and loss of work. As a result, it is one of the major illnesses addressed by England and Wales' National Health Service (NHS) Long Term Plan.

In contrast to most other nations, stroke medicine in the United Kingdom is not only the domain of neurologists; in fact, the majority of stroke consultants in the NHS are geriatricians. While stroke medicine is unquestionably interdisciplinary, properly educated neurologists are well equipped to deal with stroke and its clones. The new neurology training program in the United Kingdom will generate stroke medicine consultants, potentially expanding the stroke workforce. For the practicing neurologist, we discuss the diagnosis and treatment of acute ischemic stroke and transient ischaemic attack (TIA)[1]–[3].

Screening, Diagnosis, and Prevention:

Diagnosis:

The rapid development of a focused clinical impairment, referable to a particular location in the CNS, is the clinical presentation of stroke. Hemiparesis, hemianaesthesia (numbness on one side of the body), aphasia (language problem), homonymous hemianopia (visual field loss in both eyes), and hemispatial inattention are some of the symptoms.

Stroke diagnosis is aided by neuroimaging and needs separation from frequent mimics such as migraine, seizures, vestibular disturbances, metabolic abnormalities, and functional problems. Ischaemic stroke must also be distinguished from intracerebral bleeding. However, there are no clinical methods for doing so, and brain imaging is the only way to diagnose the condition. CT is the most common imaging modality globally, while MRI is the first-line imaging modality in a small number of centers. Rapid MRI access is a frequent restriction, and owing to metallic implants or agitation, some patients are unable to undergo an MRI[4], [5].

CT without contrast:

Intraparenchymal and extra-axial (inside the skull but outside the parenchyma) haemorrhage may be detected with near-100 percent sensitivity using non-contrast CT of the brain. Traditionally, thrombolysis treatment decisions have been based on a CT brain scan excluding bleeding in a patient with clinical symptoms of a stroke. Early ischemic alterations such as loss of grey matter–white matter distinction, which indicates early ionic oedema in the irreparably damaged brain, or a hyperdense artery, which shows acute thrombus, may lead to a positive stroke diagnosis in certain individuals. However, these symptoms may be modest, and loss of grey matter–white matter distinction in the initial few hours following a stroke might be difficult to identify.

Perfusion and CT angiography:

A static acquisition (CT angiography) or a time-resolved series of intravenous injections of iodinated contrast agent may be utilized to evaluate the cerebral vasculature (CT perfusion). CT angiography has a high sensitivity for detecting arterial stenosis and occlusion, thus it may diagnose ischemic stroke and provide light on the cause of stroke if atherosclerosis or arterial dissection are found. In all patients with ischemic stroke, CT angiography from the aortic arch to the cerebral vertex should be obtained regularly to determine eligibility for endovascular thrombectomy if this therapy is available on site or through a transfer abroad. Furthermore, CT angiography may be utilized to determine the amount of collateral flow, providing further prognostic information regarding the probable extent of tissue damage[6]–[10].

MRI:

Diffusion MRI, perfusion MRI, and T2-based sequences are only a few of the MRI sequences that may be used to evaluate various structural and functional properties of brain tissue. The most sensitive imaging technique for detecting acute ischaemia is diffusion MRI, which measures the random motion of water molecules. In areas of cytotoxic oedema, where water distribution shifts from extracellular to intracellular compartments, diffusion is limited. Within minutes after the start of an ischemic stroke, diffusion MRI becomes aberrant, and areas with diffusion restriction seldom recover to a completely normal radiological or histological appearance.

Primary Preventative Action:

Stroke incidence may be reduced significantly by population-wide measures, typically via regulatory initiatives (such as cigarette or sugar tariffs). Furthermore, both obesity and salt consumption contribute to hypertension, the leading cause of stroke, and both may be influenced at a population level by public policy changes, such as public space designs that encourage a balanced diet and exercise.

The evaluation of absolute risk of cardiovascular events informs targeted treatments to avoid stroke in high-risk patients. This evaluation takes into account the different contributions of age, sex, blood pressure, smoking, diabetes mellitus, and cholesterol levels to calculate the risk of cardiovascular events in the following five years. A high absolute risk (defined as a greater than 15% chance of having a cardiovascular event in the following 5 years) should urge aggressive

treatment of all risk factors, not just the abnormal ones. Medications to reduce blood pressure and cholesterol, as well as dietary and lifestyle changes, are often used in this therapy.

Management:

Care in a stroke unit:

Management in a geographically defined stroke unit staffed by medical, nursing, and allied health clinicians interested in stroke is likely the intervention with the greatest overall benefit, as care is guided by standardized protocols that reduce morbidity and mortality for all types and severity of stroke. The exact components that contribute to this benefit are unknown, although complications (such as aspiration pneumonia, venous thromboembolism, and pressure ulcers) are likely to be important, as is early implementation of focused secondary prevention and rehabilitation. In resource-constrained settings, stroke unit care is feasible and is a major component of the World Stroke Organization's worldwide recommendations.

Treatment with Antiplatelets:

Acute aspirin treatment within 48 hours decreases the incidence of recurrent stroke and improves the result (see Secondary prophylaxis, below). Although the benefit is less than those other reperfusion treatments, aspirin is widely used and cheap. Alternatives to aspirin, such as aspirin–dipyridamole or clopidogrel, are somewhat more efficient than aspirin in secondary stroke prevention, although they are more expensive. In high-risk individuals, a combination of aspirin and clopidogrel begun within 12 hours after a mild stroke or TIA and maintained for 3 weeks decreased the risk of recurrent stroke.

Therapies of Reperfusion:

Intravenous Thrombolysis:

There are two major intravenous thrombolysis drugs: alteplase and tenecteplase. Alteplase is a recombinant version of tissue plasminogen activator (tPA), a protein that converts plasminogen to plasmin. Plasmin then destroys fibrin, causing the thrombus to disintegrate. Antiplasmin quickly inactivates plasmin, giving it a short half-life outside the thrombus. As a result, alteplase is given as a bolus followed by a one-hour infusion. This is the gold standard in thrombolysis and is approved worldwide for ischemic stroke.

Non-contrast CT was used in the first randomized studies of thrombolysis therapy to identify individuals who were candidates for treatment. Patients with stroke mimics and those without a target artery blockage were included in the studies due to the diagnostic strategy of eliminating haemorrhage on CT and relying on clinical characteristics that suggest stroke. This likely diluted the reported treatment benefit in the trials. In the NOR-TEST study, for example, 17% of individuals were given a final diagnosis of a stroke mimic, demonstrating the difficulty of diagnosing using just non-contrast CT. Subanalyses of thrombolysis effectiveness have consistently shown that thrombolysis has a significant impact in patients with a target vascular occlusion (even minor distal occlusions) and a weak effect in individuals without vessel occlusion.

Endovascular Thrombectomy:

The release of five positive endovascular thrombectomy studies in 2015 changed the landscape of stroke reperfusion. Three neutral studies had questioned the endovascular approach's usefulness two years before; however, the positive trials utilized a new generation of more effective devices, better patient selection utilizing non-invasive imaging to verify a target artery blockage, and used quicker treatment processes.

Secondary Prevention:

Recurrent stroke prevention requires a mix of conventional methods and tailored treatments, and it is dependent on the aetiology of stroke in certain individuals. Smoking, excessive salt consumption, obesity, and physical inactivity are all lifestyle risk factors for stroke, and they are comparable to the risk factors for other cardiovascular illnesses. As a result, behavioural change efforts to improve nutrition, boost physical activity, and stop smoking remain difficult but immensely rewarding when successful.

If collateral blood flow is impaired, intensive blood pressure reduction in the immediate aftermath of an ischemic stroke has not been shown to be helpful and may be detrimental to neurological recovery. In contrast, intensive blood pressure control is critical after the acute phase of ischaemic stroke because the risk of recurrent stroke (both ischaemic and intracerebral haemorrhage) is particularly sensitive to small changes in blood pressure; epidemiological studies have suggested no lower threshold for the benefit of blood pressure lowering. The SPRINT study, which compared systolic blood pressure goals of 120 mmHg and 140 mmHg, showed that the intensive-lowering group had a lower stroke rate, but excluded patients who had already had a stroke, giving indirect support for a lower target in secondary stroke prevention. Long-term blood pressure reduction in individuals with ischemic stroke is the subject of ongoing studies.

In individuals with possible atherosclerotic causes of ischemic stroke, high-dose, high-potency statins have a well-established function in avoiding recurrent stroke. Furthermore, studies using PCSK9 inhibitors have showed promise in lowering the incidence of recurrent stroke even further. However, these medications are costly and not widely accessible. Because some individuals are unable to take statins due to muscle or liver damage, PCSK9 inhibitors may be very beneficial to them.

Recovery & Rehabilitation:

Clinical studies of rehabilitation methods after an ischemic stroke have mainly proven inconclusive or even detrimental in certain instances. The spontaneous recovery trajectory seen in patients in rehabilitation studies makes evaluating the effectiveness of the intervention difficult. The intensity of rehabilitation treatments examined to date may be insufficient; some recommendations suggest 3 hours of therapy per day, but this is not reached in many systems, and formal rehabilitation does not exist in many areas of the globe. One experiment of family-led, home-based rehabilitation in India was found to be neutral in this regard. Nonetheless, there is widespread agreement that rehabilitation is an essential part of reintegrating stroke patients back into society.

Life satisfaction:

Stroke has a significant impact on the person, their family and caregivers, as well as society as a whole. The extent of impairment is determined by the size and location of the infarct, as well as the person's pre-stroke health and functional reserve. When patients come to the emergency department, one important clinical consideration is whether reperfusion treatments have the ability to provide the patient with a quality of life that they would consider acceptable.

The modified Rankin Scale (mRS), which measures functional status after a stroke, has become the usual primary endpoint in phase III stroke studies. The mRS has been linked to patient and health-care professional ratings of quality of life. In certain cultures, an mRS score of 5 (requiring nursing home care) is equated to, or even worse than, death in terms of health utility or quality of life. However, this interpretation is not uniform, and patients' perceptions of acceptable quality of life change after a stroke, further complicating treatment choices. For example, while many people would say before a stroke that they would not want to live with a severe disability, most hemicraniectomy survivors say that, in retrospect, they would consent to the procedure if they

were faced with the same choice, despite the fact that they would be severely disabled in many cases. Dedicated patient-reported outcomes such as the PROMIS10, neuroQOL, and EQ5D are becoming increasingly frequently utilized in stroke studies, despite the fact that the mRS is a patient-reported (or carer-reported) outcome.

DISCUSSION

When the blood flow to a portion of your brain is stopped or decreased, brain tissue is deprived of oxygen and nutrients, resulting in a stroke. Within minutes, brain cells begin to die. Strokes is a life - threatening condition that requires immediate attention. Strokes are caused by ischemia (a lack of blood flow to the brain) or hemorrhage (bleeding). Brain injury and other problems may be avoided if treatment is taken early. Only one drug is now authorized to treat new strokes: tissue plasminogen activator (tPA), a clot-busting medication that works with the body's own molecules to break the blockage in the brain's blood artery that may be causing the stroke. Also, eating a nutritious diet, exercising frequently, and avoiding smoking and excessive alcohol use are the greatest ways to help prevent a stroke. These lifestyle modifications may help you avoid issues like atherosclerosis, which is when your arteries get blocked with fatty substances, and high blood pressure.

CONCLUSION

A stroke happens when the blood flow to part of your brain is stopped or diminished, stopping brain tissue from receiving oxygen and nutrients. Brain cells begin to die in minutes. A stroke is a medical emergency, and early treatment is essential. Early intervention may minimize brain damage and other consequences. Stroke medicine is a broad and rapidly developing field that provides patients suffering from the primary cause of neurological damage life-changing treatments. Stroke care will become increasingly essential in the future for neurologists, and as a specialty, we have a lot to offer, especially in terms of diagnostic ability. We may also need to further enhance our skills, such as managing critically unwell patients with general medical problems on an acute stroke unit or learning how to perform mechanical thrombectomy.

REFERENCES:

1. R. Alexandru, E. O. Terecoasă, O. A. Băjenaru, and C. Tiu, “Etiologic classification of ischemic stroke: Where do we stand?,” *Clinical Neurology and Neurosurgery*. 2017, doi: 10.1016/j.clineuro.2017.05.019.
2. J. L. Yang, S. Mukda, and S. Der Chen, “Diverse roles of mitochondria in ischemic stroke,” *Redox Biology*. 2018, doi: 10.1016/j.redox.2018.03.002.
3. G. C. Jickling and F. R. Sharp, “Blood Biomarkers of Ischemic Stroke,” *Neurotherapeutics*. 2011, doi: 10.1007/s13311-011-0050-4.
4. J. F. Meschia and T. Brott, “Ischaemic stroke,” *European Journal of Neurology*. 2018, doi: 10.1111/ene.13409.
5. Z. Dostovic, E. Dostovic, D. Smajlovic, O. C. Ibrahimagic, and L. Avdic, “Brain Edema After Ischaemic Stroke,” *Med. Arch. (Sarajevo, Bosnia Herzegovina)*, 2016, doi: 10.5455/medarh.2016.70.339-341.
6. S. Bangalore *et al.*, “Secondary prevention after ischemic stroke or transient ischemic attack,” *Am. J. Med.*, 2014, doi: 10.1016/j.amjmed.2014.03.011.
7. J. Polívka, V. Rohan, P. Ševčík, and J. Polívka, “Personalized approach to primary and secondary prevention of ischemic stroke,” *EPMA Journal*. 2014, doi: 10.1186/1878-5085-5-9.

8. N. Kapil *et al.*, "Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke," *Clinical and Applied Thrombosis/Hemostasis*. 2017, doi: 10.1177/1076029616660762.

9. B. Peng *et al.*, "Implementation of a structured guideline-based program for the secondary prevention of ischemic stroke in China," *Stroke*, 2014, doi: 10.1161/STROKEAHA.113.001424.

10. M. Paciaroni and J. Bogousslavsky, "Primary and secondary prevention of Ischemic Stroke," *European Neurology*. 2010, doi: 10.1159/000285183.